



PTO/SB/21 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/665,883
		Filing Date	September 19, 2003
		First Named Inventor	Chong-Sheng YUAN
		Art Unit	1646
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	8+36 Refs	Attorney Docket Number	466992001100

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement, 3 pages <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form 1449, 2 pages (in duplicate), listing 44 References; (36) References; Return Postcard
Remarks CUSTOMER NO. 25225		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	MORRISON & FOERSTER LLP Laurie L. Hill, Ph.D - 51,804
Signature	
Date	April 28, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: April 28, 2004	Signature: (Rhea Amid)


sd-196556



PATENT
Docket No. 466992001100

CERTIFICATE OF MAILING BY "FIRST CLASS"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on April 28, 2004.


Rhea Amid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Chong-Sheng YUAN

Serial No.: 10/665,883

Filing Date: September 19, 2003

For: DETERMINATION OF IONS USING
ION-SENSITIVE ENZYMES

Examiner: Unassigned

Group Art Unit: 1646

INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Pursuant to the USPTO notice dated July 11, 2003, waiving the requirement under 37 C.F.R. § 1.98 (a)(2)(i) to provide copies of U.S. Patents and U.S. Published Applications, copies of those references are not submitted. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of __ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of __ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)


Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 466992001100. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: April 28, 2004

Respectfully submitted,

By: 
Laurie L. Hill, Ph.D.
Reg. No. 51,804
Morrison & Foerster LLP
3811 Valley Centre Drive, Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-7955
Facsimile: (858) 720-5125



Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 466992001100

Application Number 10/665,883

Applicant

Chóng-Sheng YUAN

Filing Date September 19, 2003

Group Art Unit 1646

Mailing Date April 28 2004

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	05/1986	4,588,684	Brake	435	69.4	
	2.	08/1990	4,948,729	Piatak, Jr. et al.	435	69.1	
	3.	07/1991	5,030,563	Schendel et al.	435	69.8	
	4.	12/1992	5,171,670	Kronenberg et al.	435	68.1	
	5.	01/1998	5,710,248	Grose	530	327	
	6.	03/1999	5,885,811	Hansen	435	477	
	7.	06/1999	5,914,250	Hansen	435	69.1	
	8.	02/2001	6,194,200	Rose et al.	435	320.1	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES	NO
	9.	10/1984	EP 0 121 352	Europe				
	10.	07/1986	EP 0 186 643	Europe				X
	11.	10/1986	EP 0 196 864	Europe				
	12.	05/1989	WO 89/03886	PCT				
	13.	05/2000	WO 00/28041	PCT				

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	14.	Bastin et al., Mol. Biochem. Parasitology 77:235-239 (1996).
	15.	Baykov et al., Anal. Biochem. 171:266-70 (1988).
	16.	Biochemistry 11:1726-1732 (1972).
	17.	Chen and Katz, BioTechniques 25(1):22-24 (1998).

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 466992001100	Application Number 10/665,883
	Applicant Chong-Sheng YUAN	
	Filing Date September 19, 2003	Group Art Unit 1646
	Mailing Date April 28, 2004	

	18.	Dichtl et al., EMBO J. 16(23):7184-95 (1997).
	19.	Gil-Mascarell et al., The Plant J. 17(4):373-83 (1999).
	20.	Gumber et al., Plant Physiol. 76:40-44 (1984).
	21.	Hardy and Randall, J. Cell. Sci. Suppl. 11:29-43 (1989).
	22.	Heppel and Hilmoe, J. Bio. Chem. 188:665-676 (1951).
	23.	Hobom et al., Dev. Biol. Stand. 84:255-62 (1995).
	24.	Kuhn et al., Mol. Gen. Genet. 167(3):235-41 (1979).
	25.	Murguía et al., J. Biol. Chem. 271(46):29029-33 (1996).
	26.	Murguía et al., Science 267:232-234 (1995).
	27.	Michiels et al., Trends Microbiol. 9(4):164-8 (2001).
	28.	Nagelkerken et al., Electrophoresis 18:2694-98 (1997).
	29.	Olah et al., Biochem. 221:94-102 (1994).
	30.	Peakman et al., Nucleic Acids Res. 20(22):6111-2 (1992).
	31.	Peng et al., J. Biol. Chem. 270(49):29105-10 (1995).
	32.	Prickett et al., BioTechniques 7(6):580-4 (1989).
	33.	Roesser and Yanofsky, Nucleic Acids Res. 19(4):795-800 (1991).
	34.	Rudiger et al., BioTechniques 23(1):96-97 (1997).
	35.	Saier et al., FASEB J. 2(3):199-208 (1988).
	36.	Shimojo et al., Clin. Chem. 35(9):1992-94 (1989).
	37.	Spiegelberg et al., J. Biol. Chem. 274(19):13619-28 (1999).
	38.	Tamaoku et al., Chem. Pharm. Bull. 30:2492-2497 (1982).
	39.	Tietz, Textbook of Clinical Chemistry, p. 1841, W.B. Saunders Co., Philadelphia (1986).
	40.	Tolbert and Lameh, J. Neurochem. 70:113-119 (1998).
	41.	Tseng and Verma, Gene 169:287-288 (1996).
	42.	Wang et al., Gene 169(1):53-58 (1996).
	43.	Watson et al., Molecular Biology of the Gene, 4 th Ed., The Benjamin/Cummings Pub. Co., p. 224 (1987).
	44.	Xie et al., Endocrinology 139(11):4563-67 (1998).

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	